Clinical Trial Detail

NCT ID NCT03099356
Title Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

thyroid gland cancer

Therapies

Cyclophosphamide + Sirolimus

Age Groups: adult senior

No variant requirements are available.